Depression Screening Market Driver 2018 | Top Industry Players as Pfizer, Alkermes, Otsuka Holding & more – Says MRFR

Detail Analysis of “Global Depression Screening Market” with respect to region specific market growth and competitive analysis on the basis of major players present in the market. The study also provides a comprehensive review of restraints, Market Dynamics and drivers. – Outlook till 2023

Depression Screening Market - Scenario

The global depression screening market is expected to grow at a CAGR of 6.20% during the forecast period 2017-2023. Depression and mental health are the leading cause of disability and ill health across the globe. Depression affects an estimated one in 15 adults every year and also affects one in six people will experience depression at some time in their life. Depression can strike at any age but on average it appears during the late teens to mid-20s. Women are more likely than men to experience these depression related disorders. According to the latest estimations from (World Health Organization) WHO, more than 300 million people are now living having depression with an increase of more than 18% between 2005 and 2015. Depression is a kind of mental condition that causes individuals to experience depressed mood, loss of interest, feelings of low self-worth, disturbed sleep or appetite, low energy, and poor concentration. An individual who is suffering from depression experiences intense emotions of anxiety, hopelessness, negativity and helplessness.

Request for Sample Report at https://www.marketresearchfuture.com/sample_request/3806

Increasing prevalence of various mental disorder is one of the major driver for the market growth. Furthermore, rising funding for R&D and clinical trials are also supporting the growth of the market. Moreover, growing awareness of disorders and treatments, rapid adoption of new therapies and treatments, and technological advancement are key drivers for the market.

However, low public awareness of mental disorders and treatments in emerging nations and cultural stigma are the two major factors hindering the growth of the market.

According to a research, the mental disorders are the second leading cause of morbi-mortality in developing countries, besides that 86 of global suicides occur in low and middle income countries, which has result in low market growth.

Top Players:

Pfizer

Alkermes

Otsuka Holding

Allergan

Novartis AG and more.

Segmentation:

Segmentation of the Depression Screening Market has been based on disease type, diagnosis, treatment and end user.

Based on disease type, the market has been segmented into anxiety, mood disorders, depression, bipolar disorder, psychotic disorders, eating disorders and other mental behavious & disorders. Anxiety is the largest segment and is expected to witness a CAGR of 5.14% meanwhile, depression is the fastest growing segment.

Based on diagnosis, the market has been segmented into psychological tests, laboratory tests, depression screening tests and others. Psychological tests are the most come form of diagnosis and the evaluation of this segment is expected to reach USD 1,647.6 million by 2023.

Based on treatment, the market has been segmented into medication, brain stimulation treatments, substance abuse treatments and others. Medication is one of the most widely used forms of treatment and is estimated to value USD $ 1,949.2 million.

Ask Any Question at https://www.marketresearchfuture.com/enquiry/3806

Regional Analysis:

The Americas have the largest market share of the global depression screening market. This is largely owing to the up-to-date diagnostic and treatment options available. Research for mental health is well funded and due to awareness of mental health disorders, there is a demand for depression and mental health screening in this region, particularly in countries such as U.S and Canada.

Europe, with its second largest market share, is expected to grow significantly during the forecast period. This is attributable to similar growth patterns as the Americas. Germany, France and the U.K are the top three markets in this region, they have a strong presence of major players which further influence growth.

Asia Pacific is projected to be the fastest growing market, globally. The presence of numerous emerging economies that are experiencing an increased prevalance of mental health disorders is predicted to drive growth. Increasing awareness of mental health disorders in this region combined with a rapidly advancing healthcare sector has set this region to grow exponentially during the forecast period.

Meanwhile, the Middle East and Africa region has the smallest global market share largely owing to the low availability of relevant medical facilities and an under developed healthcare sector. However, countries in the Middle East with well-developing economies such as Qatar are expected to see some growth.

Major TOC of Depression Screening Market Research Report - Global Forecast till 2023:

1 Report Prologue

2 Market Introduction

3 Research Methodology

4 Market Dynamics

5 Market Factor Analysis

6 Global Depression Screening Market, By Disease Type

7 Global Depression Screening Market, By Diagnosis

8 Global Depression Screening Market, By Treatment

9 Global Depression Screening Market, By End User

10 Global Depression Screening Market, By Region

11 Company Share Analysis

12 Company Profiles: Top 7 Players

13 List of Tables

14 List of Figures

Check Discount Here at https://www.marketresearchfuture.com/check-discount/3806

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.